Potentiating effects of GHRH analogs on the response to chemotherapy

References

• Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4:33-43; PMID:18084344; http://dx.doi.org/10.1038/ncpendmet0677
   PubMedGoogle Scholar
• Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 2008; 68:1763-72; PMID:18729085; http://dx.doi.org/10.1002/pros.20843
   PubMed Web of Science ®Google Scholar
• Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarandi M. A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 2010; 31:1839-46; PMID:20633588; http://dx.doi.org/10.1016/j.peptides.2010.07.006
   PubMedGoogle Scholar
• Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, et al. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. Horm Metab Res 2011; 43:816-20; PMID:22009378; http://dx.doi.org/10.1055/s-0031-1287766
   PubMed Web of Science ®Google Scholar
• Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol 2011; 39:1025-32; PMID:21701777
   PubMed Web of Science ®Google Scholar
• Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 2012; 3:988-97; PMID:22941871
   PubMed Web of Science ®Google Scholar
• Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M, Halmos G. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 2012; 72:555-65; PMID:21796649; http://dx.doi.org/10.1002/pros.21458
   PubMed Web of Science ®Google Scholar
• Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol Rep 2013; 30:413-8; PMID:23624870
   PubMed Web of Science ®Google Scholar
• Jaszberenyi M, Schally AV, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Rick FG. Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. Target Oncol 2013; 8:281-90; PMID:23371031; http://dx.doi.org/10.1007/s11523-013-0264-y
   PubMed Web of Science ®Google Scholar
• Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A 2014; 111:1084-9; PMID:24395797; http://dx.doi.org/10.1073/pnas.1323102111
   PubMed Web of Science ®Google Scholar
• Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle 2014; 13:2790-7; PMID:25486366; http://dx.doi.org/10.4161/15384101.2015.945879
   PubMed Web of Science ®Google Scholar
• Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218:585-7; PMID:6812220; http://dx.doi.org/10.1126/science.6812220
   PubMed Web of Science ®Google Scholar
• Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci U S A 2006; 103:14513-8; PMID:16983095; http://dx.doi.org/10.1073/pnas.0605309103
   PubMed Web of Science ®Google Scholar
• Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A 2007; 104:1943-6; PMID:17261802; http://dx.doi.org/10.1073/pnas.0610860104
   PubMed Web of Science ®Google Scholar
• Perez R, Schally AV, Popovics P, Cai R, Sha W, Rincon R, Rick FG. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study. Oncoscience 2014; 1:665-73; PMID:25593995
   PubMedGoogle Scholar
• Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012; 11:4203-10; PMID:23095641; http://dx.doi.org/10.4161/cc.22498
   PubMed Web of Science ®Google Scholar
• Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, et al. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009; 8:3149-56; PMID:19755849; http://dx.doi.org/10.4161/cc.8.19.9698
   PubMed Web of Science ®Google Scholar
• Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick, FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 2012; 3:988-97; PMID:22941871
   PubMed Web of Science ®Google Scholar
• Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, et al. Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11:130; PMID:21486440; http://dx.doi.org/10.1186/1471-2407-11-130
   PubMed Web of Science ®Google Scholar
• Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 2010; 285:31100-6; PMID:20705611; http://dx.doi.org/10.1074/jbc.M110.155309
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28:2940-7; PMID:19581928; http://dx.doi.org/10.1038/onc.2009.180
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9:212; PMID:17705880; http://dx.doi.org/10.1186/bcr1746
   PubMed Web of Science ®Google Scholar
• Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43:374-9; PMID:18701317; http://dx.doi.org/10.1016/j.cyto.2008.07.014
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1:303-14; PMID:20049734; http://dx.doi.org/10.1002/emmm.200900043
   PubMed Web of Science ®Google Scholar
• Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A 2011; 108:3755-60; PMID:21321192; http://dx.doi.org/10.1073/pnas.1018086108
   PubMed Web of Science ®Google Scholar
• Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A 2012; 109:1655-60; PMID:22307626; http://dx.doi.org/10.1073/pnas.1120588109
   PubMed Web of Science ®Google Scholar
• Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M, Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 2012; 187:1498-504; PMID:22341819; http://dx.doi.org/10.1016/j.juro.2011.11.081
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213:374-83; PMID:17680632; http://dx.doi.org/10.1002/jcp.21223
   PubMed Web of Science ®Google Scholar
• Ansieau S. EMT in breast cancer stem cell generation. Cancer Lett 2012;338:63-8; PMID:22634497
   PubMed Web of Science ®Google Scholar
• Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012; 40:461-8; PMID:21922131
   PubMed Web of Science ®Google Scholar
• Wu ST, Sun GH, Hsu CY, Huang CS, Wu YH, Wang HH, Sun KH. Tumor necrosis factor-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism. Exp Biol Med (Maywood) 2011; 236:1022-9; PMID:21856755
   PubMed Web of Science ®Google Scholar
• Wu X-Z. Origin of Cancer Stem Cells: The Role of Self-Renewal and Differentiation. Ann Surg Oncol 2007; 15:407-14; PMID:18043974; http://dx.doi.org/10.1245/s10434-007-9695-y
   PubMed Web of Science ®Google Scholar
• Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4:33-43; PMID:18084344
   PubMedGoogle Scholar
• Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, Zhou J, Ding YQ, Li JM. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010; 9(4):295-302; PMID:20026903; http://dx.doi.org/10.4161/cbt.9.4.10666
   PubMed Web of Science ®Google Scholar
• Bermejo-Rodríguez C, Pérez-Caro M, Pérez-Mancera PA, Sánchez-Beato M, Piris MA, Sánchez-García I. Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics 2006; 87:113-8; PMID:16311016; http://dx.doi.org/10.1016/j.ygeno.2005.09.014
   PubMed Web of Science ®Google Scholar
• Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci U S A 2006; 103:14513-8; PMID:16983095; http://dx.doi.org/10.1073/pnas.0605309103
   PubMed Web of Science ®Google Scholar
• Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget 2013; 4:422-32; PMID:23518876
   PubMed Web of Science ®Google Scholar
• Popovics P, Schally AV, Szalontay L, Block NL, Rick FG. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget 2014; 5:4567-78; PMID:24994120
   PubMed Web of Science ®Google Scholar
• Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG. Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. Oncotarget 2013; 4:751-60; PMID:23744510
   PubMed Web of Science ®Google Scholar
• Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M, Rick FG. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. Oncotarget 2012; 3:686-99; PMID:22824624
   PubMed Web of Science ®Google Scholar
• Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, et al. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer 2014; 14:847; PMID:25410881; http://dx.doi.org/10.1186/1471-2407-14-847
   PubMed Web of Science ®Google Scholar
• Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res 2010; 42:781-6; PMID:20665426; http://dx.doi.org/10.1055/s-0030-1261955
   PubMed Web of Science ®Google Scholar
• Seitz S, Schally AV, Treszl A, Papadia A, Rick F, Szalontay L, Szepeshazi K, Ortmann O, Halmos G, Hohla F, et al. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anticancer Drugs 2009; 20:553-8; PMID:19491659; http://dx.doi.org/10.1097/CAD.0b013e32832d190b
   PubMed Web of Science ®Google Scholar
• Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K, Halmos G. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides 2009; 30:1643-50; PMID:19524629; http://dx.doi.org/10.1016/j.peptides.2009.06.007
   PubMed Web of Science ®Google Scholar
• Seitz S, Buchholz S, Schally AV, Jayakumar AR, Weber F, Papadia A, Rick FG, Szalontay L, Treszl A, Koster F, et al. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anticancer Drugs 2013; 24:150-7; PMID:23080077; http://dx.doi.org/10.1097/CAD.0b013e32835a7e29
   PubMed Web of Science ®Google Scholar
• Schally AV, Engel JB, Emons G, Block NL, Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 2011; 8:11-25; PMID:21034424; http://dx.doi.org/10.2174/156720111793663598
   PubMed Web of Science ®Google Scholar
• Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol 2014; 20:6102-12; PMID:24876732; http://dx.doi.org/10.3748/wjg.v20.i20.6102
   PubMed Web of Science ®Google Scholar
• Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, et al. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides 2014; 52:104-12; PMID:24373935; http://dx.doi.org/10.1016/j.peptides.2013.12.010
   PubMed Web of Science ®Google Scholar
• Jaszberenyi M, Rick FG, Popovics P, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Schally AV. Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 2014; 111:781-6; PMID:24379381; http://dx.doi.org/10.1073/pnas.1322622111
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007; 3:157-67; PMID:17237842; http://dx.doi.org/10.1038/ncpendmet0399
   PubMedGoogle Scholar
• Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother 2013; 14:2237-47; PMID:23984804; http://dx.doi.org/10.1517/14656566.2013.834328
   PubMed Web of Science ®Google Scholar
• Rick FG, Schally AV. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2014; PMID:25512159; http://dx.doi.org/10.1016/j.urolonc.2014.11.006
   PubMed Web of Science ®Google Scholar
• Crawford ED, Rove KO, Schally AV, Rick FG, Block NL, Beveridge TJR, Dahdal DN, Marshall DC. The Role of the FSH System in the Development and Progression of Prostate Cancer. Am J Hematol Oncol 2014; 10:5-13.
   Google Scholar
• Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71:736-47; PMID:20945403; http://dx.doi.org/10.1002/pros.21289
   PubMed Web of Science ®Google Scholar
• Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate 2013; 73:873-83; PMID:23280565; http://dx.doi.org/10.1002/pros.22633
   PubMed Web of Science ®Google Scholar
• Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, et al. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci U S A 2013; 110:2617-22; PMID:23359692; http://dx.doi.org/10.1073/pnas.1222355110
   PubMed Web of Science ®Google Scholar
• Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, et al. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle 2012; 11:2518-25; PMID:22751419; http://dx.doi.org/10.4161/cc.20900
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab M, Schally AV, Rick FG, Szalontay L, Block NL, Jorda M, Mahmoud O, Markoe A, Shi Y-F, Reiner T, et al. Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis. J Radiat Oncol 2012; 1:389-96; http://dx.doi.org/10.1007/s13566-012-0031-1
   Google Scholar
• Farkas R, Pozsgai E, Schally AV, Szigeti A, Szigeti E, Laszlo Z, Papp A, Gomori E, Mangel L, Horvath PO, et al. Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer. J Cancer Res Clin Oncol 2012; 138:387-95; PMID:22160161; http://dx.doi.org/10.1007/s00432-011-1110-1
   PubMed Web of Science ®Google Scholar